Clinical data | |
---|---|
Trade names | Strimvelis |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
DrugBank |
Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence, sold under the brand name Strimvelis, is a medication used to treat severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID).[1]
ADA-SCID is a rare inherited condition in which there is a change (mutation) in the gene needed to make an enzyme called adenosine deaminase (ADA).[1] As a result, people lack the ADA enzyme.[1] Because ADA is essential for maintaining healthy lymphocytes (white blood cells that fight off infections), the immune system of people with ADA-SCID does not work properly and without effective treatment they rarely survive more than two years.[1]
Strimvelis is the first ex vivo autologous gene therapy approved by the European Medicines Agency (EMA).[2]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search